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Abstract: Despite the availability of various specific treatments, most patients with chronic 
pain (CP) consider their pain problem as undertreated. Recently, multiple sclerosis (MS) patients 
who were given an intensive 3-day social cognitive treatment with the participation of support 
partners experienced lasting improvements in health-related quality of life (HRQoL) and self-
efficacy. In this study, a similar intervention was given to treatment-resistant CP patients with 
stressors, relational problems with support partner, and distress, anxiety or depression. Before 
and 1, 3, and 6 months after the intervention, patients completed the Euro-Qol 5 Dimensions 5 
Levels (EQ-5D-5L) and Impact on Participation and Autonomy (IPA) questionnaires (primary 
outcomes), and the Survey Of Pain Attitudes (SOPA), the Four-Dimensional Symptom Question-
naire (4DSQ) (distress, depression, anxiety, and somatization), and Visual Analog Scale for pain 
intensity, whereas the support partners completed the Caregiver Strain Index (CSI) questionnaire. 
Differences between baseline and post-treatment were tested via paired t-tests (significance level 
0.05). Of the 39 patients who were included, 34 (87.2%) completed the 3-day treatment. At 1, 3, 
and 6 months, improvements were seen in EQ-5D-5L-Index (+40.6%; +22.4%; +31.7%), Health 
Today (+61.8%; +36.3%; +46.8%), Control attitude (+45.8%; not significant [NS]; +55.0%) and 
decreases in IPA-Problems (−14.8%; NS; −20.4%), Harm attitude (−18.9%; −15.0%; −17.7%), 
Distress (−17.7%; −31.8%; −37.1%), and Depression (−37.4%; −31.4%; −35.7%) scores. The 
CSI score had decreased by −29.0%, −21.4%, and −25.9%, respectively. In conclusion, after 
an intensive 3-day social cognitive intervention, treatment-resistant CP patients experienced 
substantial and lasting improvements in HRQoL and in problematic limitations to participation 
and autonomy, in association with improvements in pain attitudes, depression, and distress. To 
assess whether this innovative approach may be an effective treatment for this subgroup of CP 
patients, future randomized controlled studies are needed. 
Keywords: goal setting, depression, anxiety, distress, caregiver, caregiver strain, pain attitudes
Introduction
Despite increased understanding of the factors contributing to the development of 
chronic pain (CP), the population burden of CP is rising.1 In the Netherlands, about 
18% of the general population experience a moderate to severe pain condition, and 
studies performed in different settings have demonstrated that CP affects between 
10% and 30% of the adult population in Europe.2–4 CP is associated with a number 
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of  negative outcomes including reduced health-related qual-
ity of life (HRQoL), impairment of function, limited daily 
activities, isolation, depression, and helplessness.1,4,5 As a 
result, CP constitutes a considerable burden to patients, their 
families, and the society.5
Of Dutch CP patients with a pain score of 5 or higher on a 
Visual Analog Scale (VAS) (0–10), 57% is being treated.5 As 
to treatment modalities, 41% of the patients use analgesics, 
mainly nonsteroidal anti-inflammatory drugs. Among the 
non-pharmaceutical therapies, physiotherapy, acupuncture, 
and massage are the most frequent ones, whereas cognitive 
behavioral treatment is hardly applied.5 However, despite 
various specific treatment options and recommendations, 
>56% of CP patients in the Netherlands declare that their 
pain problem is undertreated and 78% of patients with a 
VAS score of ≥5 state that they experience their treatment 
as insufficient.5 
Analogous to the situation in multiple sclerosis (MS), a 
chronic and disabling disorder of the central nervous sys-
tem, pain-induced disability may lead to helplessness and 
negatively affect patients’ independence and autonomy.6,7 
The negative experience of losing independence may cause 
CP patients to underestimate their capacities, as a result of 
which they have a risk to further lose existing functions. As 
a reaction to the loss of autonomy, patients tend to external-
ize or objectify their pain and want medications or medical 
cure to solve the pain problem. Moreover, CP patients often 
expect their significant others to be solicitous in response to 
their pain. Indirectly, informal caregivers, like partners, fam-
ily, and friends, are confronted as well with the impact of an 
increase in disabilities and a decrease in independence. In 
fact, the patients’ continuous and increasing appeal to support 
partners may result in an ever-increasing pressure on the latter.
For patients with MS and their support partners, the Can 
Do treatment was developed, which is an intensive multidis-
ciplinary 3-day social cognitive intervention.6,7 The Can Do 
treatment is based on the social cognitive theory, according 
to which psychosocial functioning is determined by recipro-
cal interactions between personal factors, behavior, and the 
environment.8,9 The goal is to enable patients to regain access 
to their capabilities and thus to improve their autonomy and 
HRQoL. In persons with relapsing remitting (RR) MS, it 
was observed that half a year after this treatment, mental and 
physical HRQoL had increased by 22.3% and 17.6%, respec-
tively.6 In a subsequent study, it was found that 12 months 
after treatment, RRMS patients had an increased physical 
HRQoL (+15.0%) and decreased depression (−29.8%) and 
anxiety (−25.9%).10
Given the chronic and disabling nature of both CP and 
MS, and the resemblances in the processes that may lead 
to loss of autonomy and HRQoL, it was considered that 
an intervention similar to that in MS might be effective in 
treatment-resistant CP patients. Therefore, based on the Can 
Do treatment for RRMS patients, the Challenge intervention 
was developed and assessed for its potential effects. 
Methods
The Challenge
The concept, components, and multidisciplinary approach 
of the Challenge intervention are based on those of the Can 
Do treatment in MS, which has been described in detail.6,7,10 
Methodologically, it is of note that CP patients and their 
professional caregivers are often convinced that the pain 
problem can be controlled and cured by medication, injec-
tions, or other invasive procedures, whereas MS patients are 
familiar with the notion that their disorder is as yet incurable. 
Hence, the dependence and loss of autonomy in CP patients 
are expectedly greater than that in MS patients.
Concept
The purpose of the intervention is to unveil and stimulate 
existing capacities, with “stressor” as the central concept.6,7,10 
The Challenge is primarily sociologically oriented6,7,10 and 
aims to identify those stressors that limit patients in their 
physical, psychological, or social role activities.6,7,10 To 
reduce stressors, the intervention is based on five principles: 
identification and reduction of existing stressors; client-
centeredness; inclusion of support partner (partner or a 
significant informal caregiver); group sessions; and the cen-
tral notions of self-reliance, autonomy, and acceptance.6,7,10 
The intervention aims to reduce relevant stressors, to push 
personal boundaries, and to establish new ones by making 
maximal use of the existing potential.6,7,10 In order to put the 
patient’s capacities in a realistic context, central mottos are 
“Can,” “Will,” “Choose,” “Open up to others,” and “Do.”6,7,10 
Thus, patients get an increased awareness of their potential 
which may result in better self-management and interactions 
with professional caregivers.6,7,10 
Components
The components of the Challenge are similar to those of 
the Can Do treatment in MS, which have been described in 
detail.6,7,10 In brief, large and small group sessions, consulta-
tions, a theater evening, and an optional collective activity 
at the start of the day.6,7,10 In the plenary sessions, patients 
and partners make optimal use of their capacities, learn how 
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 0
2-
Ja
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research  2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2727
Improved quality of life after social cognitive intervention
to support and stimulate others, and how to give feedback 
to the team of professionals;6,7,10 in sessions with half of the 
participants, major stressors are identified and each person 
names at most two realizable aims.6,7,10 Then, during group 
consultations, the participants check if the goals can be 
realized.6,7,10 Depending on his/her aim(s), each participant 
registers for various small sessions, which form the actual 
intervention.6,7,10 In “Body” sessions, coached by a physio-
therapist, physical capacities are explored;6,7,10 the “Feeling” 
sessions, coached by a psychiatric nurse and a psychiatrist, 
deal with the exploration of the emotional potential;6,7,10 and 
in the “Life” sessions, coached by a registered pain consultant 
and an anesthesiologist specialized in pain, the potentials 
regarding daily living with CP are explored.6,7,10 Moreover, 
participants can also choose for the relaxation sessions 
“Dance” and “Physical.”6,7,10 
Multidisciplinary team
The multidisciplinary team includes a psychiatrist, psychiat-
ric nurse, anesthesiologist specialized in pain, registered pain 
consultant, physiotherapist, and dance therapist. 
Study design and organization
Various clinical outcomes were prospectively measured in CP 
patients and their support partners before and after treatment. 
The determination of the size of the study group was based 
on two considerations: first, in the observational study, in 44 
MS patients, statistically significant and clinically relevant 
changes were found in the RR subgroup of 20 patients,6 
and, second, the presumed similarities in psychological 
mechanisms underlying the HRQoL impairments in RRMS 
and CP patients. 
The Challenge is based on the Can Do treatment that was 
developed by the National Multiple Sclerosis Foundation 
(Rotterdam, the Netherlands), PsyToBe, and members of 
the Can Do team.6,7,10 The study was initiated and financed 
by DC Klinieken Rotterdam (Rotterdam, the Netherlands). 
The Challenge interventions were organized by DC Klinieken 
Rotterdam, and the study was designed and performed by 
MS4 Research Institute (Nijmegen, the Netherlands). Patients 
were recruited by DC Klinieken Rotterdam from the outpa-
tient population of the clinic.
The eligibility criteria for patients were 1) CP diagnosis, 
2) positive pre-screening (see below), 3) able and willing to 
participate in the study and the study-related assessments, 
4) written informed consent, and 5) having a support part-
ner who is willing and able to participate in the study and 
the study-related procedures.6,7,10 The eligibility criteria for 
 support partners were 1) willing and able to participate in 
the study and 2) written informed consent.6,7,10 
The pre-screening was performed by an anesthesiologist 
specialized in pain (AH) and a registered pain consultant 
(YMM-K) (DC Klinieken Rotterdam) in an outpatient setting 
during regular visits. Patients were assessed for no or insuf-
ficient response to standard treatments (treatment-resistance), 
evidence suggestive of the existence of stressors, evidence 
suggestive of relational problems between patient and sup-
port partner, and abnormally high score(s) on the distress, 
anxiety, or depression sub-scale(s) of the Four-Dimensional 
Symptom Questionnaire (4DSQ).
Assessment schedule and data acquisition
Data were obtained through the online versions of psycho-
metrically validated questionnaires and VAS at baseline 
(1 week before treatment) and 1, 3, and 6 months after treat-
ment. This assessment schedule was similar to that used in the 
Can Do treatment studies in MS patients. After having given 
their consent, the patients were sent a personal code to gain 
access to the study website.10 The assessments were performed 
online via the LimeSurvey software.10 The questionnaires had 
fixed items, and responses were captured automatically.10 The 
processes of data acquisition and storage were in accordance 
with the European Union regulations regarding online medical 
data.10 Before submission, the questionnaires were verified 
automatically for completeness. In case patients had not filled 
in the questionnaires within 1 week after schedule, they were 
given a phone call by the help desk as a reminder.10
Outcomes and outcome measures
The primary study outcomes were changes in 1) HRQoL 
and 2) participation and autonomy at 6 months after treat-
ment. Secondary outcomes were changes in 1) pain intensity, 
2) pain attitudes, and 3) distress, anxiety, depression, and 
somatization 6 months after treatment. The tertiary outcome 
was change in care-related strain perceived by the support 
partner 6 months after treatment. 
Primary outcome measures
HRQoL was assessed by using the Euro-Qol 5 Dimensions 
5 Levels (EQ-5D-5L) questionnaire, a standardized measure 
of health status.11,12 The EQ-5D-5L provides a descriptive 
profile, a single index value for health status, and a VAS 
score for Health Today.12 The instrument is designed for self- 
completion by respondents and is cognitively  undemanding.12 
The EQ-5D-5L comprises f ive dimensions: mobility, 
 self-care, usual activities, pain/discomfort, and anxiety/
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depression.11,13 Each dimension has five levels: no problem, 
slight problems, moderate problems, severe problems, and 
extreme problems or not able to.11 The respondent is asked to 
indicate his/her health state by ticking in the box against the 
most appropriate statement in each of the five dimensions, 
which results in a 1-digit number expressing the level selected 
for that dimension. A resulting 5-digit number describes 
the respondent’s health state, and the health states may be 
converted into a single index value.14 The VAS records the 
respondent’s answer to the question “We would like to know 
how good or bad your health is today” by means of a vertical 
VAS (0–100) with endpoints labeled “The best health you 
can imagine” and “The worst health you can imagine.” The 
EQ-5D-5L-Index value and the VAS score were calculated.
According to its authors,6 the 
Impact on Participation and Autonomy (IPA) questionnaire 
is a 32-item, validated, generic, self-report instrument for the 
quantification of limitations in participation and autonomy in 
people with chronic health conditions. The IPA-Limitations 
subscale assesses perceived limitations in participation and 
autonomy in relation to 32 different life situations across 
five subscales: autonomy indoors, family role, autonomy 
outdoors, social life and relationships, and work and educa-
tion. Items are rated on a 5-point scale from 0 (very good) to 
4 (very poor), and a higher score indicates a higher limitation 
to participation and autonomy. The IPA-Problems subscale 
examines the extent to which these limitations are experi-
enced as problematic, by assessing nine different areas of 
participation and autonomy: mobility, self-care, activities in 
and around the house, looking after money, leisure, social 
life and relationships, paid or voluntary work, education 
and training, and helping and supporting other people. The 
perceived problems are graded on a 3-point scale ranging 
from 0 (no problem) to 2 (severe problems), and a higher IPA-
Problems score indicates a greater experience of problems.15,16
Secondary outcome measures
Pain intensity was assessed through a VAS (0–10) by using 
three questions: 1) “What is the degree of your pain at this 
moment?” 2) “What was the degree of your pain at a moment 
that the pain was minimal?” 3) “What was the degree of your 
pain at a moment that the pain was maximal?”
Patients’ attitudes and beliefs about pain were assessed 
by means of the Survey Of Pain Attitudes (SOPA) question-
naire.17 The SOPA is a validated 57-item assessment in which 
respondents are asked to indicate their level of agreement 
with each statement on a 5-point Likert scale: “very untrue,” 
“somewhat untrue,” “neither true nor untrue,” “somewhat 
true,” and “very true.” The SOPA consists of seven scales that 
are divided into two areas – adaptive beliefs and maladaptive 
beliefs. According to its authors,
[...] the SOPA’s adaptive beliefs are (a) Control (the extent 
to which a patient believes he or she can control his or her 
pain) and (b) Emotion (the extent to which a patient believes 
that his/her emotions have an impact on his/her experience 
of pain). The maladaptive beliefs are (a) Disability (the extent 
to which a patient believes he or she is disabled by his or her 
pain), (b) Harm (the extent to which a patient believes that 
pain is an indication that he or she is damaging himself or 
herself and that he or she should avoid exercise), (c) Medi-
cation (the extent to which a patient believes that medication 
is an appropriate treatment for chronic pain), (d) Solicitude 
(the extent to which a patient believes that others, especially 
family members, should be solicitous in response to his or her 
experience of pain) and (e) Medical Cure (the extent to which a 
patient believes in a medical cure for his or her pain problem).17
Higher scores indicate higher adaptive (Control and Emo-
tions) and higher maladaptive (Disability, Harm, Medication, 
Solicitude, and Medical Cure) beliefs.17 
The 4DSQ is a validated self-rating questionnaire that 
measures nonspecific general distress, depression, anxiety, 
and somatization.18 The 4DSQ comprises 50 items distributed 
over four scales, the reference period is the past week, and 
the response categories are “no,” “sometimes,” “regularly,” 
“often,” and “very often or constantly.” The responses are 
scored as 0 for “no,” 1 for “sometimes” and 2 for the other 
response categories, and the item scores are summated to 
scale scores. The Distress scale comprises 16 items and has 
a score range of 0–32, the Depression scale comprises 6 
items and has a range of 0–12, the Anxiety scale comprises 
12 items and has a range of 0–24, and the Somatization scale 
comprises 16 items and has a range of 0–32.18 
Tertiary outcome measure
The burden to support partners was assessed by the Caregiver 
Strain Index (CSI).19 The CSI is a 13-item instrument that 
identifies strain of informal care providers.19 Each item is 
scored yes (=1) or no (=0), and addition of the item scores 
yields the CSI score (0–13). A higher CSI score indicates a 
higher caregiver strain. A score of ≥7 indicates a high level 
of stress, and therefore a need for more in-depth assessment 
to facilitate appropriate intervention (positive screen).19,20
Ethical aspects
The protocol was approved by the “Medisch-Ethische Toet-
sing Onderzoek Patiënten” (METOPP), an ethical review 
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 0
2-
Ja
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research  2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2729
Improved quality of life after social cognitive intervention
board residing in Tilburg, the Netherlands; CCMO (Central 
Committee on Research Involving Human Subjects) number: 
NL49040.028.14 (http://www.ccmo.nl/en). The study was 
carried out in compliance with the Declaration of Helsinki 
(Ethical Principles for Medical Research Involving Human 
Subjects version 2013; 64th World Medical Association Gen-
eral Assembly, Fortaleza, Brazil, October 2013) (www.wma.
net) and the Dutch Medical Research Involving Human Sub-
jects Act of 1999 (www.wetten.overheid.nl/BWBR0009408). 
Patients received no financial incentive or reward to partici-
pate. As the intervention, like the Can Do treatment in MS, 
forms an exceptional physical and mental strain, it may lead 
to a transitory increase in pain or to changes in mood and 
emotions. The experience of the team members safeguarded 
that adverse effects were immediately addressed. 
Data analysis
For all outcomes, the absolute values at baseline and at 1, 3, 
and 6 months after the intervention were calculated (mean, 
standard deviation [SD], minimum, and maximum). The 
changes at 1, 3, and 6 months, expressed as percentages of 
baseline, were calculated as well (mean, standard error of 
the mean [SEM], and median). As the purpose of the study 
was to assess whether and when clinically relevant changes 
occurred after treatment, we compared each post-treatment 
outcome with its baseline value using multiple paired Stu-
dent’s t-tests and expressed the change as percentage of the 
baseline value. To prevent multiple testing from interfering 
with a sound interpretation of the data, conclusions were 
based on the 6-month primary outcomes. 
Post hoc we explored the relationship between the pain, 
HRQoL, and distress/anxiety scores, and between the EQ-
5D-5L and VAS scores at baseline and at 6 months by cal-
culating Pearson’s correlation coefficient (r).
For all tests, a P-value <0.05 was considered significant. 
The statistical analyses were performed at the Department for 
Health Evidence of the Radboud University Medical Centre 
(Nijmegen, the Netherlands). 
Results
Patients
Of the ~700 patients who were seen at the outpatient clinic 
between January and July 2014, 87 were positive for treat-
ment resistance and existence of stressors and of relational 
problems between patient and support partner. Of these, 75 
patients had abnormally high score(s) on distress, anxiety, or 
depression 4DSQ subscale(s), and 39 of these were willing 
to participate. Thus, 39 patients with support partners were 
included, completed the baseline assessments, and started 
the Challenge. 
The patients had 49 CP diagnoses. The most frequent 
diagnoses were lumbar radicular pain (n=15), failed back 
surgery syndrome (n=8), cervical radicular pain (n=7), 
fibromyalgia (n=4), postoperative cervical pain (n=2), and 
postradiation pain (n=2), whereas abdominal pain, arthrosis, 
chondropathy, eye pain, lumbar disk collapse, lumbar pain, 
pain left buttock of unknown origin, post-traumatic stress 
disorder, status after lumbar disk fracture, whiplash, and 
chronic widespread pain were each diagnosed in one patient. 
Ten patients had two diagnoses. 
The patients used in total 37 different pain-related medi-
cations. The median number of drugs used per patient was 3 
(minimum 0, maximum 5). The medications that were most 
frequently used were tramadol (n=10), amitriptylin (n=9), 
paracetamol (n=9), pregabalin (n=7), etoricoxib (n=6), and 
fentanyl (n=6). Other medications were buprenorfin, diclof-
enac, and ibuprofen (each four times); celecoxib, citalopram, 
gabapentin, paroxetine, and sumatriptan (each three times); 
clonazepam, codeine, oxazepam, oxycodone, rizatriptan, 
and venlafaxine (each twice); and clomipramine, diazepam, 
dipiperon, duloxetine, fluoxetine, imipramine, lidocaine, 
lithium, lorazepam, mirtazapine, morphine, prilocaine, ser-
traline, temazepam, zolmitriptan, zolpidem, and zoplicone 
(each once).
The marital status were: married (n=18), living together 
with partner (n=8), living alone (n=6), living alone with 
child(ren) (n=4), and living apart together (n=3). The 
employment status were: receiving sickness benefit (n=11), 
employed (n=8), unemployed (n=5), receiving disability 
benefit (n=5), retired (n=4), and voluntary work (n=2). In 
seven patients, the employment status was unknown, and 
three patients were partly employed, partly receiving sickness 
or disability benefit.
Four interventions were given in 2014 (March, May, 
September, and November), each during 3 consecutive days, 
in the hotel The Arendshoeve (Bergambacht, the Nether-
lands). Nine to ten patients and support partners participated 
in each intervention. Five (12.8%) patients and their support 
partners prematurely discontinued, whereas 34 (87.2%) 
completed the 3 days. The reasons for early discontinuation 
were: “Treatment is irritating and humiliating” (male, 31 
years, pain duration 1 year, failed back surgery syndrome, 
group 1); “This is nonsense, information beforehand was 
insufficient” (male, 38 years, pain duration 6 years, lum-
bar radicular pain, group 1); “I absolutely don’t want to 
work in groups” (male, 44 years, pain duration 30 years, 
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abdominal pain, group 3); “I am too restless for the treat-
ment, I am unable to manage it” (female, 70 years, pain 
duration 2 years, lumbar radicular pain, group 3); “I am 
very angry about all this” (female, 51 years, pain duration 
20 years, cervical radicular pain, group 4). In consequence 
of the reasons given by the two dropout patients in the first 
group, for the groups 2–4 a less confronting approach was 
adopted, without however changing the very concept of 
the Challenge. 
Considering that in the dropout patients the intended 
changes would have occurred partially or not at all, these 
patients were not included in the effectiveness analyses. Of 
the 34 patients who completed the intervention, 26 (76.5%) 
were female and eight (23.5%) male. Their mean age was 
48.9 years (SD 12.6) (minimum 20.0, maximum 74.0) and 
the mean pain duration was 8.4 years (SD 9.6) (minimum 
0.5, maximum 33.2). All 34 analyzable patients performed 
the baseline assessment, 33 of these (97.1%) performed the 
1-month assessment, 28 (82.4%) the 3-month assessment, 
and 29 (85.3%) the 6-month assessment.
HRQoL, participation, and autonomy
The mean, SD, minimum, and maximum values for the 
EQ-5D-5L-Index, the VAS Health Today, and the IPA- 
Limitations and IPA-Problems scores at baseline and 1, 3, 
and 6 months after intervention are presented in Table 1. At 
6 months, the EQ-5D-5L-Index, the VAS Health Today score, 
and the IPA-Problems score were evidently increased as 
compared to baseline (all P≤0.007) (Table 1; Figure 1A–C). 
Pain intensity, pain attitudes, distress, 
depression, anxiety, and somatization
The mean, SD, minimum, and maximum values for the VAS 
Actual, Minimum and Maximum pain intensity, the attitudes 
SOPA Control, Emotion, Disability, Harm,  Medication, 
Solicitude, and Medical, and the 4DSQ symptoms Dis-
tress, Depression, Anxiety, and Somatization at baseline 
and 1, 3, and 6 months after intervention are presented in 
Table 2. Statistically significant and substantial changes were 
observed in Actual pain intensity (decreased), the attitudes 
Control (increased) and Harm (decreased), and the symptoms 
Distress and Depression (both decreased) (all P≤0.0095) 
( Figure 1D–G). In addition, statistically significant decreases 
were also seen in the attitudes Disability (P=0.0461), Solici-
tude (P=0.0457), and Medical Cure (P=0.0300), and the 
symptoms Anxiety (P=0.0204) and Somatization (P=0.0173) 
(Table 2, Figure 1H). 
Caregiver strain
The mean CSI score at 6 months was lower than before 
intervention (P=0.0222) (Table 3; Figure 1I). Whereas before 
intervention, 41% of the support partners had a CSI ≥7, at 
6 months post-intervention, this was 32%.
Percentage changes from baseline
To assess whether statistically significant changes could 
be interpreted as clinically relevant, that is, improvement, 
the post-intervention values were expressed as percentages 
of the baseline values. It was found that at 6 months, the 
EQ-5D-5L-Index and VAS Health Today had increased by 
31.7% (mean) and 46.8% (mean), respectively, whereas the 
IPA-Problems score had decreased by −20.4% (mean) (Table 
4A). As to the secondary outcomes, the attitudes Control 
and Harm had changed by +55.1% (mean) and −17.7% 
(mean), respectively, and the symptoms Distress, Depres-
sion, and Somatization had decreased by −37.1% (mean), 
−35.7% (mean), and −16.8% (mean), respectively (Table 
4B). Moreover, the Actual pain intensity had decreased by 
−14.6% (mean). Finally, the CSI score had decreased by 
−25.9% (mean) at 6 months (Table 3). 
Table 1 Mean (SD) (minimum–maximum) EQ-5D-5L-Index, VAS Health Today, IPA-Limitations, and IPA-Problems values at baseline 
and at 1, 3, and 6 months after intervention
Outcome 
measures
Baseline (n=34) Month 1 (n=33) Month 3 (n=28) Months 6 (n=29)
EQ-5D-5L-Index 0.43 (0.21) (−0.03–0.79) 0.57 (0.22) (0.02–0.84)
(P<0.0001)
0.54 (0.24) (0.11–0.87) 
(P=0.0091)
0.56 (0.22) (0.17–0.87) 
(P=0.0012)
VAS Health Today 37.6 (16.2) (7–65) 55.9 (19.9) (12–80) 
(P<0.0001)
48.1 (24.1) (10–85) 
(P=0.0162)
46.4 (25.3) (8–83) 
(P=0.0021)
IPA-Limitations 2.1 (0.6) (1–3) 1.9 (0.7) (1–3) 
(P=0.0335)
2.1 (0.7) (0–3) 
(P=0.9971)
1.9 (0.08) (1–3) 
(P=0.1138)
IPA-Problems 1.3 (0.4) (0–2) 1.1 (0.5) (0–2) 
(P=0.0552)
1.1 (0.5) (0–2) 
(P=0.0276)
1.1 (0.6) (0–2) 
(P=0.0070)
Note: P-values for comparisons between baseline and post-intervention.
Abbreviations: EQ-5D-5L, Euro-QoL 5 dimensions 5 levels; IPA, Impact on Participation and Autonomy; SD, standard deviation; VAS, visual analog scale.
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Post hoc analyses
It was found that at baseline (n=34) none of the pain scores 
correlated with the EQ-5D-5L-Index, the VAS Health Today, 
the 4DSQ Anxiety score, or the 4DSQ Distress scores (all 
P>0.06). However, the 4DSQ Distress score correlated with 
the EQ-5D-5L-Index (Pearson’s r =−0.58; P=0.000) and the 
Health Today score (r=−0.343, P=0.047), and the 4DSQ 
Anxiety score also correlated with the EQ-5D-5L-Index 
(r=−0.474; P=0.005) score. 
At 6 months (n=29), the Actual, Minimal, and Maximal 
pain scores correlated with the Health Today score (r=−0.57, 
P=0.001; r=−0.37, P=0.048; r=−0.51, P=0.005), and the Actual 
and Maximal pain scores also correlated with the EQ-5D-
5L-Index (r=−0.56, P=0.002; r=−0.55, P=0.002). Similar to 
baseline, the 4DSQ Distress score correlated with the EQ-5D-
5L-Index (r=−0.77; P=0.000) and the Health Today score 
(r=−0.501, P=0.006), and the 4DSQ Anxiety score correlated 
with the EQ-5D-5L-Index (r=−0.563; P=0.001).
Figure 1 Scatter plots visualizing individual responses for those outcomes that showed statistically significant changes at six months. The X-axis represents the score at 
baseline, and the Y-axis the score at 6 months after the intervention.
Abbreviations: CSI, Caregiver Strain Index;  EQ-5D-5L, Euro-Qol 5 Dimensions 5 Levels; IPA, Impact on Participation and Autonomy;  SOPA, Survey Of Pain Attitudes; 
VAS, visual analog scale.
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The correlation between the EQ-5D-5L-Index and VAS 
Health Today score at 6 months (r=0.836, P=0.000) was 
higher than that at baseline (r=0.604, P=0.000). 
Discussion
A half year after having received an intensive social cognitive 
intervention, in which their support partners participated, 
treatment-resistant CP patients with evidence of stressors, 
relational problems with support partner, and distress, 
anxiety or depression showed an increased HRQoL and less 
problems with limitations to participation and autonomy. 
The 6-month data also suggest beneficial changes in the 
attitudes Control and Harm, and the symptoms Distress 
and Depression. 
As percentage changes of 15%–20% or higher may 
be considered clinically relevant,21 the degree of HRQoL 
increase (EQ-5D-5L-Index +32%, Health Today +47%) and 
of the decrease in problematic limitations to participation 
Table 2 Mean (SD) (minimum–maximum) values for VAS Actual, Minimum and Maximum pain, SOPA attitudes Control, Emotion, 
Disability, Harm, Medication, Solicitude, and Medical, and 4DSQ symptoms Distress, Depression, Anxiety, and Somatization at baseline 
and at 1, 3, and 6 months after intervention
Outcome measures Baseline (n=34) Month 1 (n=33) Month 3 (n=28) Months 6 (n=29)
Actual pain (0–10) 6.7 (1.9) (0–10) 6.1 (2.1) (2–10) 
(P=0.2808)
6.1 (1.7) (2–9) 
(P=0.4385)
5.7 (2.3) (2–9) 
(P=0.0095)
Minimal pain (0–10) 3.7 (1.8) (0–7) 3.6 (2.0) (0–7) 
(P=0.7704)
4.0 (2.0) (1–8) 
(P=0.2668)
3.7 (2.0) (0–8) 
(P=0.6676)
Maximal pain (0–10) 8.3 (2.2) (0–10) 7.8 (1.7) (4–10) 
(P=0.3093)
7.8 (1.8) (0–9) 
(P=0.6590)
8.0 (1.8) (2–10) 
(P=0.2676)
Control 47.2 (6.3) (34–59) 50.0 (9.6) (28–68) 
(P=0.0476)
49.1 (10.6) (26–68) 
(P=0.1867)
52.2 (10.2) (24–78) 
(P=0.0035)
Emotion 52.1 (11.5) (30–80) 55.1 (12.5) (38–80) 
(P=0.0602)
52.7 (12.1) (30–80) 
(P=0.8262)
54.4 (11.1) (30–80) 
(P=0.4765)
Disability 54.2 (9.0) (40–74) 50.7 (10.0) (28–72) 
(P=0.0233)
53.4 (9.7) (40–72) 
(P=0.6226)
51.1 (12.6) (25–74) 
(P=0.0461)
Harm 55.2 (8.1) (42–74) 51.0 (9.8) (34–76) 
(P=0.0016)
54.0 (10.5) (36–80) 
(P=0.0256)
51.8 (10.3) (28–72) 
(P=0.0027)
Medication 47.5 (6.7) (31–59) 47.7 (6.6) (37–62) 
(P=0.9313)
47.4 (6.6) (35–59) 
(P=0.8103)
46.8 (5.7) (33–59) 
(P=0.5029)
Solicitude 48.2 (10.2) (32–80) 44.8 (10.0) (32–63) 
(P=0.0025)
45.2 (10.8) (32–65) 
(P=0.0538)
46.1 (12.1) (32–72) 
(P=0.0457)
Medical cure 54.8 (7.7) (34–75) 52.1 (6.3) (34–63) 
(P=0.0095)
51.6 (8.0) (36–75) 
(P=0.0070)
50.1 (9.8) (27–66) 
(P=0.0300)
Distress 20.4 (8.1) (7–32) 15.8 (8.9) (1–32) 
(P=0.0018)
14.5 (10.4) (0–32) 
(P<0.0001)
14.4 (10.4) (0–32) 
(P<0.0001)
Depression 4.7 (4.5) (0–12) 3.0 (3.7) (0–12) 
(P=0.0023)
3.5 (4.6) (0–12) 
(P=0.0262)
3.6 (4.4) (0–12) 
(P=0.0072)
Anxiety 5.7 (5.8) (0–20) 4.0 (4.9) (0–20) 
(P=0.0271)
3.6 (5.2) (0–21) 
(P=0.1853)
3.6 (5.3) (0–21) 
(P=0.0204)
Somatization 17.2 (4.5) (9–26) 14.7 (5.1) (7–26) 
(P=0.0098)
14.5 (5.2) (4–26) 
(P=0.0233)
14.0 (6.9) (3–29) 
(P=0.0173)
Note: P-values for comparisons between baseline and post-intervention.
Abbreviations: SD, standard deviation; SOPA, Survey Of Pain Attitudes; VAS, visual analog scale, 4DSQ, Four-Dimensional Symptom Questionnaire.
Table 3 CSI (mean) (SD) (minimum–maximum) values at baseline and at 1, 3, and 6 months after intervention; CSI percentage changes 
(mean) (SEM) (median) post-intervention; and the number (Nr) (percentage) of support partners with a CSI ≥7 at various time points
Outcome measures Baseline (n=29) Month 1 (n=27) Month 3 (n=26) Month 6 (n=25)
CSI (0–13) 5.6 (3.3) (0–11) 3.7 (2.7) (0–9) 
(P=0.0008)
4.1 (3.4) (0–11) 
(P=0.0264)
4.4 (3.7) (0–12) 
(P=0.0222)
CSI % Δ (SEM) (median)
−29.0% (9.7) (−37.5%) 
(P=0.0065)
−21.4% (10.2) (−25.0%) 
(P=0.0467)
−25.9% (8.7) (−26.1%) 
(P=0.0069)
Nr. (%) CSI ≥7 12 (41%) 4 (15%) 5 (19%) 8 (32%)
Note: P-values for comparisons with baseline.
Abbreviations: CSI, Caregiver Strain Index; SD, standard deviation; SEM, standard error of mean.
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and autonomy (IPA-Problems −20.4%) may be qualified as 
improvements. Similarly, the changes in the Control (+55%) 
and Harm (−18%) attitudes, and in the symptoms Distress 
(−35%) and Depression (-35%) may be qualified as clinically 
relevant as well. Alternatively, an indication about clinical 
relevance can also be obtained by expressing changes as SD 
of the baseline scores.21 Thus, compared to baseline, at 6 
months the EQ-5D-5L-Index was +0.62 SD baseline, Health 
Today +0.54 SD baseline, IPA-Problems −0.50 SD baseline, 
Control attitude +0.70 SD baseline, Harm attitude −0.42 
SD baseline, Distress −0.74 SD baseline, and Depression 
−0.24 SD baseline. So, except for Depression, two different 
approaches suggest that the statistically significant changes 
mentioned above are indeed clinically relevant. Moreover, 
the improvements seemed to occur as early as 1 month after 
the intervention and were more or less maintained up to 6 
months later.
Assessment of HRQoL is increasingly considered 
essential in patients with chronic disorders. HRQoL is an 
overall measure of well-being from the patient’s perspective 
which provides a comprehensive measure of health status. 
It can be defined as the functional effect of an illness and 
its  consequent therapy upon a patient, as perceived by the 
patient.22 In general, in CP patients, HRQoL is inversely 
related to the degree of pain.1 The average mental well-being 
score for men and women in severely limiting CP is at a 
similar level to that of the lowest scoring 10% of people who 
are pain free.1 Against this background, the improvement in 
EQ-5D-5L-Index (mean +31.7%) and VAS Health Today 
(+46.8%) in our selection treatment-resistant patients sug-
gests that an eventual effectiveness of the Challenge approach 
could indeed be relevant from the patient’s perspective. 
Although the limitations in participation and autonomy 
had not changed, the degree at which patients experienced 
Table 4 Mean percentage change (standard error) (median) from baseline for the primary and secondary outcome measures
Outcome measures Month 1 (n=33) Month 3 (n=28) Months 6 (n=29)
(A) Primary outcome measures
EQ-5D-5L-Index +40.6% (9.9) (+32.2%) 
(P=0.0003)
+22.4% (8.6) (+11.4%) 
(P=0.0149)
+31.7% (10.9) (+10.4%) 
(P=0.0072)a
VAS Health Today +61.8% (12.5) (+37.5%) 
(P<0.0001)
+36.3% (12.8) (+23.0%) 
(P=0.0086)
+46.8% (21.4) (+16.7%) 
(P=0.0374)
IPA-Limitations NSb NS NS
IPA-Problems 
−14.8% (5.4) (−12.7%) 
(P=0.0103)
NS
−20.4% (7.5) (−11.1%) 
(P=0.0115)
(B) Secondary outcome measures
Actual pain NS NS
−14.6 (6.2) (−0.0%) 
(P=0.0248)
Minimal pain NS NS NS
Maximal pain NS NS NS
Control +45.8% (18.7) (+23.5%) 
(P=0.0197)
NS +55.1% (18.3) (+31.6%) 
(P=0.0055)
Emotion +50.7% (20.9) (11.2) 
(P=0.0212)
NS NSc
Disability NS NS NS
Harm
−18.9% (8.1) (−21.4%) 
(P=0.0267)
−15.0% (5.8) (−9.6%) 
(P=0.0158)
−17.7% (6.4) (−9.5%) 
(P=0.0095)
Medication NS NS NS
Solicitude
−16.8% (7.5) (−9.1%) 
(P=0.0328)
NS NS
Medical cure NS
−13.2% (6.4) 16.5%) 
(P=0.0487)
NS
Distress
−17.7% (7.6) (−21.9%) 
(P=0.0252)
−31.8% (6.9) (−19.8%)
(P<0.0001)
−37.1% (6.6) (−33.3%) 
(P<0.0001)
Depression
−37.4% (8.8) (−33.3%) 
(P=0.0003)
−31.4% (10.6) (−8.3%) 
(P=0.0076)
−35.7% (8.7) (−33.3%) 
(P=0.0004)
Anxiety NS NS NS
Somatization
−11.7% (4.6) (−16.7%) 
(P=0.0172)
−12.9% (6.2) (−15.1%) 
(P=0.0455)
−16.8% (6.7) (−13.0%) 
(P=0.0181)
Notes: P-values for comparisons with baseline. aComparison based on n=26; NS (P>0.05). bNonsignificant (P<0.05). cP=0.0556. 
Abbreviations: EQ-5D-5L, Euro-QoL 5 Dimensions 5 Levels; IPA, Impact on Participation and Autonomy; NS, not significant; VAS, visual analog scale.
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limitations as problematic had improved. This may relate 
to the co-occurring increase in the Control attitude, which 
indicate that patients believed stronger that they could control 
their pain. Similarly, a stronger belief to be able to control 
pain-induced limitations may be thought to result in experi-
encing these limitations as less problematic. 
CP patients more often have problems with depression or 
anxiety than people with no pain, and the likelihood of report-
ing depression or anxiety increases markedly as pain grade 
increases.1 In the UK, 70% of men and 68% of women with 
high disability-severely limiting pain report being depressed 
or anxious, compared with 26% of men and 27% of women 
with low disability-low intensity pain, and 17% and 22% 
among those with no CP.1 A recent study in Spain showed 
that about 30% of CP patients felt sad/very sad or anxious/
very anxious, and 47.2% considered their pain affected 
their families.23 Against this background, it is likely that the 
improvements that occurred in depression and distress have 
been instrumental in improving HRQoL.
Interestingly, 6 months after intervention, the CSI score 
had decreased by a mean of −25.9% (−0.36 SD baseline), 
indicating that the patients’ improvements were mirrored 
by a decrease in caregiver burden. It is of note that in the 
CSI, “strain” refers to those enduring problems that have 
the potential for arousing threat, a meaning that establishes 
“strain” and “stressor” as interchangeable concepts.19 Despite 
that care giving has been recognized as an activity with both 
perceived burdens and benefits,20,24 caregivers are prone to 
depression, grief, fatigue, changes in social relationships, and 
physical health problems.20 Moreover, perceived caregiver 
burden has been associated with patient reports of unmet 
needs.20 Therefore, screening tools are useful to identify care 
givers who would benefit from a more comprehensive assess-
ment.20 As to the CSI, a total score of ≥7 is a positive screen 
and indicates a need for more in-depth assessment.19,20 Vari-
ous domains have been identified that should be addressed 
in a comprehensive assessment of the care giving process: 
the patient’s cognitive status and problematic behaviors, and 
the caregiver’s perception of role overload or deprivation 
in key relationships, goals, or activities.25 Given that CP 
patients and their support partners both participated in the 
Challenge, and in view of the clinically relevant changes in 
patient-reported outcomes, it may be hypothesized that an 
improvement in patients’ problematic behaviors as well as 
in caregivers’ perception of role overload have contributed 
to the decrease in caregiver strain.
According to the social cognitive theory, patients can 
acquire knowledge directly by observing others within 
the context of social interactions and experiences.8,9 When 
patients observe others performing a behavior and the con-
sequences of that behavior, they remember the sequence of 
events and use this information to guide subsequent behav-
iors.8,9 The Challenge is a group intervention with support 
partners, in which CP patients are challenged to take action 
and are stimulated to use their potentials and to perform new 
behavior. By observing each other’s behavior and experienc-
ing the consequences, patients are able to perform this newly 
learned behavior in daily life, thus reducing the predominance 
of their pain and increasing their quality of life.
The Challenge intervention methodology for CP patients 
is based on the Can Do methodology designed around 
patients with MS. CP patients and MS patients have several 
similarities, that is, both suffer from chronic disorders caus-
ing anxiety, sleep disturbances, and depressive symptoms. 
Despite these similarities, it is important to note the differ-
ences between the Challenge intervention and the Can Do 
treatment. In the studies on the Can Do treatment, MS patients 
were included by a patient organization (National Multiple 
Sclerosis Foundation, the Netherlands), and patients were 
not screened for predictors that would supposedly enhance 
the chance of success of the Can Do approach. In contrast, 
CP patients for the Challenge intervention were included in a 
pain referral center by an anesthesiologist specialized in pain 
and a registered pain consultant, using a pre-screening for 
the existence of no or insufficient response to standard treat-
ments, evidence suggestive of the existence of stressors, evi-
dence suggestive of relational problems between patient and 
supporting partner, and abnormally high levels of distress, 
anxiety, or depression. By using this pre-screening procedure, 
only patients with chronic, complex, and treatment-resistant 
pain syndromes were eligible, being effectively 10%–15% 
of the patient population of the center. This difference in 
patient selection may in part explain why at 6 months in the 
CP group the mean increases of the two HRQoL measures 
(EQ-5D-5L-Index and Health Today) were +31.7% and 
+46.8%, respectively, whereas in the RRMS group the physi-
cal and mental HRQoL scores had on average increased by 
+17.6% and +22.3%, respectively.10 Moreover, in the RRMS 
patients, the IPA-Problems score showed a nonsignificant 
change of −3.9%, whereas the decrease in the CP patients 
was on average −20.4%.10
Another difference is that RRMS patients are famil-
iar with the notion that their disorder is as yet incurable. 
On the contrary, CP patients are often convinced that the 
 anesthesiologist specialized in pain can control or cure the 
pain. Therefore, CP patients are likely to remain hopeful to be 
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relieved of the pain, thus becoming dependent on the treating 
physician with a greater loss of autonomy. Furthermore, in 
contrast to RRMS patients, high levels of stress work coun-
terproductive for CP patients: their decreased autonomy and 
loss of control cause a higher sensitivity to stress compared 
to RRMS patients. The aim of the Challenge intervention is 
to reduce the relevant stressors, and this is accomplished by 
confrontation techniques, that is, to push personal boundaries 
and to establish new personal boundaries by making maximal 
use of the existing potential. In CP patients, the confrontation 
techniques may be experienced as an additional stressor. In 
consequence, the stress level may rise too high, leading to 
anxiety symptoms, a fight-flight-freeze reaction and in the 
end in regressive behavior and patient dropout. When we 
noticed this during the first session, we used less confront-
ing techniques. 
The additional explorative analyses suggest that the inter-
vention may have resulted in a stronger relationship between 
pain and quality of life, without substantially affecting the 
existing relationship between distress and quality of life. 
Given that at 6 months patients had a higher Control attitude, 
a lower Harm attitude, were less depressed, and experienced 
their limitations on participation and autonomy as less prob-
lematic, it may be hypothesized that after the intervention 
these four factors impacted quality of life to a much lesser 
degree than at baseline, thus leading to a relatively stronger 
effect of pain on quality of life.
The questionnaires used in this study were psychometri-
cally validated instruments. The EQ-5D-5L is a preference-
based measure of HRQoL that enables comparisons between 
various patient populations and healthy controls. It is practi-
cal, reliable, valid, and responsive in patients with chronic 
diseases,26,27 including CP.28,29 Compared to the EQ-5D-3L, 
it shows improved measurement properties, a reduced ceil-
ing effect, and improved discriminatory power.30 In patients 
with persistent oro-facial pain, the EQ-5D-5L has been 
demonstrated to have sufficient convergent validity.31 An 
additional advantage is that the data can be used in cost-utility 
analyses.32 The IPA has been developed in the Netherlands for 
use in patients with various chronic disorders, among others 
musculoskeletal disease and nervous system disease.15,16 The 
quality of psychometric testing of the IPA has been found 
to be good.33 The SOPA was developed to assess a patient’s 
attitudes and beliefs about pain, specifically those pain 
attitudes thought to be most closely related to the outcomes 
of cognitive behavioral treatment for pain.17 There is an 
 extensive amount of evidence supporting the SOPA as a reli-
able and valid measure of pain beliefs, and it has been widely 
applied in clinical research. The 4DSQ has been developed 
in the Netherlands, and evidence supports its reliability and 
measurement invariance in the general Dutch population.34 
It can be used in clinical practice and in research.18 The CSI 
was specifically developed for the measurement of caregiver 
burden, establishing a construct validity in the areas of ex-
patient characteristics, subjective perceptions of the care-
taking relationship by caregivers, and emotional health of 
caregivers.19 In a study in the Netherlands, the CSI showed 
good reproducibility and moderate responsiveness.35 In all, 
the questionnaires used seem appropriate for the detection 
of clinically relevant changes after an intervention. 
The social cognitive concept and the findings of the 
Challenge intervention are in line with recent reports in the 
literature. A study in patients with chronic musculoskeletal 
pain indicates that the impact of emotions and cognition 
upon pain-related disability can be better understood when 
the social context of patients, especially family function, is 
considered;36 and in veterans, posttraumatic stress disorder 
symptoms were associated with punishing responses to 
pain from significant others.37 In young CP patients, family 
functioning was associated with functional ability,38 and 
parent distress may increase the risk of poor response to 
psychological treatment.39
In CP patients, the social domain can have a greater 
impact on patients’ quality of life than any other aspect 
of pain,40 and recent research has focused on CP patients’ 
ability to participate in social and recreational activities.41 
Against this background, the clinically relevant decrease 
in problematic limitations to participation and autonomy is 
in favor of the Challenge. In line with the social cognitive 
approach, group sessions were an integral part of the inter-
vention, aimed to discover and exchange information about 
personal stressors and emotions. Interestingly, a qualitative 
study of cognitive behavioral group treatment in CP patients 
showed that an active role with self-revelation and exchanges 
of thoughts and feelings in the group may be instrumental 
in achieving therapeutic success.42 The exercise component 
in the Challenge is supported by an observational study in 
refractory CP patients, which found that a combination of 
behavioral therapy and exercise given to groups of indi-
viduals was followed by improvements in disability and 
pain intensity.43 Finally, a recent systematic review of CP 
in youth showed that depression, anxiety, and pain intensity 
were associated with higher levels of disability,38 and thus 
lends support to the supposed role of changes in depression, 
anxiety, and pain intensity in effectuating an improvement in 
HRQoL in our patients.
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It has been suggested that psychological treatments, 
like social cognitive interventions, should be differentiated, 
for example, according to diagnosis, symptom severity or 
predictors.41,44 Actually, the Can Do treatment for RRMS 
patients and the Challenge intervention for CP patients differ 
in the degree at which confronting techniques are applied. A 
comparison of the Can Do and the Challenge study results 
suggests that in CP patients, prescreening for treatment 
resistance and starting points for the Challenge approach – 
that is, stressor(s), relational problems with support partner 
and high level of distress, anxiety, or depression – may have 
been crucial in bringing about a seemingly greater effect. 
Recent randomized controlled trials showed that in persons 
with chronic widespread pain, a short course of telephone-
based cognitive behavioral therapy was effective and highly 
cost-effective long term45 and that in patients on sick leave 
due to chronic low back pain, cognitive behavioral therapy 
and physical group exercise were not effective compared 
to a brief, cognitive intervention.46 Hence, it is conceivable 
that (subgroups of) CP patients may benefit from a limited, 
outpatient version of the Challenge.
Our study has several limitations. First, as there was no 
control group, it cannot be concluded that there is a causality 
between the intervention and the improvements we noticed. 
Second, the patients were recruited in a single pain exper-
tise and referral center in the Netherlands (DC Klinieken 
Rotterdam) and therefore generalizability of our findings 
may be questioned. Third, it is likely that especially patients 
experiencing a high level of pain and pain-related problems 
have volunteered for an intensive experimental intervention 
and that therefore a regression-to-the-mean effect has been 
operative. Fourth, uncontrolled studies cannot differentiate 
the intervention’s effect from a placebo effect; although after 
6 months, a placebo effect is unlikely to fully explain the 
observed improvements. Fifth, after the first group, we modi-
fied the intervention slightly by adopting a less confronting 
approach; this, however, did not affect the very concept of 
the intervention. Sixth, the participants were not instructed to 
complete the questionnaires on the same time of day, and we 
did not ask for the time point of completion; given the vari-
ability in pain and other symptoms, this may have interfered 
with the validity of the study results.
Conclusion
Treatment-resistant CP patients with stressor(s), relational 
problems with support partner, and distress, anxiety or 
depression experienced improvements in HRQoL and in 
problematic limitations to participation and autonomy, a 
half year after having received an intensive social cognitive 
intervention with participation of support partners. Support 
partners experienced less caregiver strain. Our findings sug-
gest that clinically relevant changes in the attitudes Control 
and Harm, and in Depression and Distress may have been 
operative in bringing about these improvements. To conclu-
sively demonstrate the effectiveness and clinical relevance of 
the Challenge intervention in treatment-resistant CP patients, 
a randomized controlled trial is needed.
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